Deutsche Bank upgraded Acadia Healthcare (ACHC) to Buy from Hold with a price target of $75, up from $45. The company has been an underperformer throughout 2024 due to a “steady stream of negative news,” which accelerated in September when a New York Times report alleged that Acadia was keeping patients against their will in its psychiatric hospitals, the analyst tells investors in a research note. Deutsche has turned bullish on the stock “simply because” it believes “there is a price for every asset.” At $40 per share, Acadia Healthcare presents an attractive risk/reward, the firm contends. Deutsche says its bullish is based on the replacement value of Acadia beds, its leveraged buyout scenario model, the stock’s valuation and its studying of history to anticipate the future.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACHC:
- Cantor Fitzgerald ‘cautious’ on Acadia after survey of inpatient psych referrers
- Acadia down 1% following NY Times expose on ‘fraud and fakery’ at clinics
- Acadia Healthcare falsifies records at methadone clinics, NY Times says
- Acadia Healthcare price target lowered to $43 from $76 at Barclays
- Acadia Healthcare price target lowered to $64 from $94 at RBC Capital